[go: up one dir, main page]

MX347400B - Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. - Google Patents

Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.

Info

Publication number
MX347400B
MX347400B MX2012007682A MX2012007682A MX347400B MX 347400 B MX347400 B MX 347400B MX 2012007682 A MX2012007682 A MX 2012007682A MX 2012007682 A MX2012007682 A MX 2012007682A MX 347400 B MX347400 B MX 347400B
Authority
MX
Mexico
Prior art keywords
fatty liver
vaccine composition
development
atherosclerosis disease
novel
Prior art date
Application number
MX2012007682A
Other languages
English (en)
Other versions
MX2012007682A (es
Inventor
Pérez Torres Armando
Mas Oliva Jaime
Alicia Delgado Coello Blanca
Guadalupe García González Víctor
Original Assignee
Univ Nac Autónoma De México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nac Autónoma De México filed Critical Univ Nac Autónoma De México
Priority to MX2012007682A priority Critical patent/MX347400B/es
Priority to EP13809203.6A priority patent/EP2868327B1/en
Priority to PCT/MX2013/000078 priority patent/WO2014003531A1/es
Priority to ES13809203T priority patent/ES2873517T3/es
Priority to US14/411,233 priority patent/US9539312B2/en
Publication of MX2012007682A publication Critical patent/MX2012007682A/es
Publication of MX347400B publication Critical patent/MX347400B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición vacunal de nanopartículas micelares para la administración intranasal que comprende un péptido carboxilo terminal de la proteína transferidora de ésteres de colesterol (CETP) conformado como SEQ ID NO: 1 como un inmunógeno, 2, 3-dibifitanil-o-sn-glicerol (calarqueol) de la arqueobacteria Thermus aquaticus, lisofosfolípido y fosfatidilcolina en un vehículo farmaceúticamente aceptable.
MX2012007682A 2012-06-28 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. MX347400B (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2012007682A MX347400B (es) 2012-06-29 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
EP13809203.6A EP2868327B1 (en) 2012-06-29 2013-06-26 Nasal vaccine against the development of atherosclerosis disease and fatty liver
PCT/MX2013/000078 WO2014003531A1 (es) 2012-06-28 2013-06-26 Vacuna de aplicación nasal contra el desarrollo de la enfermedad aterosclerótica y el hígado graso
ES13809203T ES2873517T3 (es) 2012-06-29 2013-06-26 Vacuna nasal contra el desarrollo de la enfermedad aterosclerótica e hígado graso
US14/411,233 US9539312B2 (en) 2012-06-28 2013-06-26 Nasal vaccine against the development of atherosclerosis disease and fatty liver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012007682A MX347400B (es) 2012-06-29 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.

Publications (2)

Publication Number Publication Date
MX2012007682A MX2012007682A (es) 2013-12-30
MX347400B true MX347400B (es) 2017-04-18

Family

ID=49783566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007682A MX347400B (es) 2012-06-28 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.

Country Status (5)

Country Link
US (1) US9539312B2 (es)
EP (1) EP2868327B1 (es)
ES (1) ES2873517T3 (es)
MX (1) MX347400B (es)
WO (1) WO2014003531A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201627318A (zh) 2014-10-22 2016-08-01 臺北醫學大學 膽固醇酯轉運蛋白抗原肽及其融合蛋白以及其組合物及應用
TW201711677A (zh) * 2015-08-06 2017-04-01 奧托德里克有限公司 磷脂-膽固醇酯奈米調配物及其相關方法
CN106729681B (zh) * 2016-12-21 2020-02-21 上海交通大学医学院附属新华医院 一种提高抗原免疫原性的纳米化载体蛋白平台

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
EP0831881B1 (en) * 1995-06-06 2003-03-12 Avant Immunotherapeutics, Inc. Cetp for increasing hdl cholesterol level
JP2000502087A (ja) * 1995-12-15 2000-02-22 ナショナル リサーチ カウンシル オブ カナダ アジュバンドおよび送達賦形剤としての、アーケオソーム類、補酵素ｑ▲下１０▼を含有するアーケオソーム類、および補酵素ｑ▲下１０▼を含有する他の種類のリポソーム類
US6846808B1 (en) 1996-05-01 2005-01-25 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6284553B1 (en) 1999-02-16 2001-09-04 Advanced Micro Devices, Inc. Location dependent automatic defect classification
US7749721B2 (en) 1999-12-13 2010-07-06 Universidad Nacional Autónoma de México Immuno enzymatic quantification method for cholesterol ester transferring protein (CETP)
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AT500835B1 (de) 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament
US20080220028A1 (en) * 2006-12-15 2008-09-11 National Research Council Of Canada Archaeal polar lipid aggregates for administration to animals

Also Published As

Publication number Publication date
WO2014003531A1 (es) 2014-01-03
EP2868327A1 (en) 2015-05-06
MX2012007682A (es) 2013-12-30
EP2868327B1 (en) 2021-03-03
EP2868327A4 (en) 2015-07-22
US9539312B2 (en) 2017-01-10
US20150328296A1 (en) 2015-11-19
ES2873517T3 (es) 2021-11-03

Similar Documents

Publication Publication Date Title
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
MX350258B (es) Emulsiones cationicas de aceite en agua.
TR201904758T4 (tr) İmmünoterapiye yönelik RNA formülasyonu.
IL286515A (en) Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
MX343410B (es) Emulsiones cationicas de agua en aceite.
MY176018A (en) Composition useful for the treatment of lipid metabolism disorders
BR112015022476A2 (pt) composições de oxaliplatina de lipossoma para terapia de câncer
PH12015500221A1 (en) Oil-in-water emulsion comprising deamidated protein
BR112015022415A2 (pt) composições de cisplatina lipossômica para terapia contra câncer
NZ747847A (en) Lipid compositions
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
NZ702472A (en) Oil/water-emulsion-type topical compositions containing a retinoid
AR105144A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
IN2014CN03214A (es)
WO2012014073A3 (en) Vaccines against pregnancy-associated malaria
CY1123453T1 (el) Σκευασμα rna για ανοσοθεραπεια
NZ631131A (en) Reconstituted hdl formulation
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
PH12014501144A1 (en) Oil-in-water cosmetic compositions
MX2012007682A (es) Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
WO2013007637A3 (en) Cosmetic compositions in the form of water-in-oil emulsions including a jasmonic acid derivative and a silicone surfactant
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor

Legal Events

Date Code Title Description
FG Grant or registration